Двойное слепое, рандомизированное исследование, направленное на сравнение арипипразола и оланзапина у пациентов с шизофренией

В. В. Флейшхакер, Р. Д. Макквейд, Romesh Markus et al. · Социальная и клиническая психиатрия · 2009

Background: Few studies have directly compared the efficacy and tolerability of atypical agents. Methods: This multicenter, randomized, double-blind study compared the efficacy and tolerability of aripiprazole (n=355) with olanzapine (n=348) in patients with schizophrenia experiencing acute relapse. After a 6-week acute treatment phase, patients with Clinical Global Impression-Improvement =1-3 or ≥20% reduction in the Positive and Negative Symptom Scale (PANSS) Total score could progress to the 46-week outpatient extension phase. Co-primary study objectives were to compare efficacy at Week 6 and weight gain liability from baseline to Week 26. Results: The mean olanzapine dose was 15.4 mg/day compared with a mean aripiprazole dose of 23.0 mg/day. More patients treated with olanzapine (47%) completed the 52-week study than those treated with aripiprazole (39%); time to discontinuation was significantly in favor of olanzapine (p

Cited by 0 works.

Authors